JP2019531742A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531742A5
JP2019531742A5 JP2019520685A JP2019520685A JP2019531742A5 JP 2019531742 A5 JP2019531742 A5 JP 2019531742A5 JP 2019520685 A JP2019520685 A JP 2019520685A JP 2019520685 A JP2019520685 A JP 2019520685A JP 2019531742 A5 JP2019531742 A5 JP 2019531742A5
Authority
JP
Japan
Prior art keywords
receptor
antigen
tcr
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520685A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2018073393A5 (enExample
JP2019531742A (ja
JP7236380B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/076800 external-priority patent/WO2018073393A2/en
Publication of JP2019531742A publication Critical patent/JP2019531742A/ja
Publication of JP2019531742A5 publication Critical patent/JP2019531742A5/ja
Publication of JPWO2018073393A5 publication Critical patent/JPWO2018073393A5/ja
Application granted granted Critical
Publication of JP7236380B2 publication Critical patent/JP7236380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520685A 2016-10-19 2017-10-19 治療に適したtalエフェクターヌクレアーゼ(talen)改変同種異系細胞 Active JP7236380B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662410187P 2016-10-19 2016-10-19
US62/410,187 2016-10-19
DKPA201770240 2017-03-31
DKPA201770240 2017-03-31
PCT/EP2017/076800 WO2018073393A2 (en) 2016-10-19 2017-10-19 Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy

Publications (4)

Publication Number Publication Date
JP2019531742A JP2019531742A (ja) 2019-11-07
JP2019531742A5 true JP2019531742A5 (enExample) 2020-11-19
JPWO2018073393A5 JPWO2018073393A5 (enExample) 2023-01-25
JP7236380B2 JP7236380B2 (ja) 2023-03-09

Family

ID=60268352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520685A Active JP7236380B2 (ja) 2016-10-19 2017-10-19 治療に適したtalエフェクターヌクレアーゼ(talen)改変同種異系細胞

Country Status (5)

Country Link
US (1) US20230138915A1 (enExample)
EP (1) EP3529265A2 (enExample)
JP (1) JP7236380B2 (enExample)
AU (1) AU2017347685B2 (enExample)
CA (1) CA3041039A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008082A2 (pt) 2018-11-07 2021-08-10 Crispr Therapeutics Ag terapia contra o câncer com células imunitárias anti-liv1
US20230332104A1 (en) * 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
CN117129690B (zh) * 2023-09-26 2025-06-06 杭州师范大学 Grhl1在her2-乳腺癌诊断及预后评估中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3133545C (en) * 2012-05-25 2023-08-08 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
DK3004337T3 (da) * 2013-05-29 2017-11-13 Cellectis Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system
ES2782125T3 (es) 2014-03-11 2020-09-10 Cellectis Método para generar linfocitos T compatibles para trasplante alogénico
AU2016214301B2 (en) * 2015-02-06 2022-05-19 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
BR112017020750A2 (pt) * 2015-03-27 2018-06-26 Harvard College células t modificadas e métodos de produção e utilização das mesmas
EP4108255A1 (en) * 2015-10-05 2022-12-28 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
KR102824067B1 (ko) * 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2022066290A (ja) Fc受容体様5を標的とするキメラ抗原受容体およびその使用
BR112020007710A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
CA3094468A1 (en) Methods of producing cells expressing a recombinant receptor and related compositions
US20220193135A1 (en) Modified immune effector cell and preparation method therefor
JP2020500530A5 (enExample)
JP2023552998A (ja) 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
US20250297268A1 (en) Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
US12152251B2 (en) T cells with improved functionality
JP2021510081A (ja) 抗体修飾キメラ抗原受容体修飾t細胞及びその使用
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
IL297547A (en) Therapeutic interventional particles for the corona virus
CN110511912A (zh) 免疫细胞的功能调节
JP2019531742A5 (enExample)
AU2023273885A1 (en) Polynucleotides targeting nr4a3 and uses thereof
US12410231B2 (en) Natural killer cell products and methods
JP7236380B2 (ja) 治療に適したtalエフェクターヌクレアーゼ(talen)改変同種異系細胞
US20220031747A1 (en) Foxp1-ablated chimeric cells
WO2023207390A1 (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
JP2023541694A (ja) がん治療剤としての二重特異的抗原結合分子を有するcar発現ナチュラルキラー細胞の生成方法及び組成物
WO2023164688A1 (en) Allogeneic therapeutic cells
WO2025194140A1 (en) Thermally controlled gene expression and uses thereof
US20240366670A1 (en) Allogenic therapeutic cells with reduced risk of immune rejection
CN117157407A (zh) 编码ap-1转录因子的密码子优化的核苷酸序列
HK40083622A (en) Modified immune effector cell and preparation method therefor